An experimental drug designed to aid severely ill patients after hospitalization is not more effective than standard treatments for reducing the risk of blood clots, a study has confirmed.

A common drug that stops bleeding in patients with severe hemophilia, a rare bleeding disorder in which the blood doesn't clot normally, may also be able to prevent such bleeds altogether.

Certain birth control pills are more likely to cause serious blood clots than others. The newer forms of progesterone combined with hormonal contraceptives carry a higher risk of venous thromboembolism (VTE) than older forms of the pill.

Patients with a certain blood type may have a naturally lower risk of dying after heart surgery. Two added blood proteins mean that patients with AB blood are 20 percent are more likely to survive.

There may be a window shortly after menopause in which women can slow the development of clogged arteries through a method as simple as taking soy protein supplements.

Patients who have previously suffered from a blood vessel blockage and received a medication-coated stent to prop the artery open may have a lower risk of developing another blockage or having a heart attack.

For patients with coronary disease, taking medication to prevent blood clots for up to two years provides no additional benefit in avoiding adverse heart events as compared to taking it for six months.

Treatments are improving for heart attack patients with obstructed blood vessels. Newer technologies are both safer and more effective.

Atrial fibrillation, a common heart arrhythmia, is generally treated with a standard drug warfarin. However, a study suggests a new drug might provide the same treatment, but with a lower risk of stroke and embolism.

It's not uncommon for individuals to get small blood clots in veins just beneath the skin that easily heal without treatment. However, it may put those patients at a higher risk of developing a deadly blood clot.